GlassScriptPhysician profile
Stephanie Madonis
NPI 1972997922
$13,770.48
in general payments reported to CMS, 2019-2025
26 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $292 · 2021: $1,232 · 2022: $8,627 · 2023: $1,525 · 2024: $1,392 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,794 · Travel and Lodging: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.38 |
| Travel and Lodging | $570.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,761.24 | 2021-2025 | Corevalve Evolut R, Ffrangio, Cg Future |
| Abbott Laboratories | $2,225.46 | 2022-2023 | Supera, Perclose Proglide |
| Penumbra, INC. | $1,716.42 | 2022 | |
| Edwards Lifesciences Corporation | $1,671.34 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,637.82 | 2021-2024 | Watchman, Avvigo Guidance System, S-Icd System Magnet |
| Abiomed | $510.35 | 2022-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $393.35 | 2022-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $364.94 | 2019-2023 | Farxiga, Andexxa |
| Inari Medical, INC. | $285.12 | 2022 | |
| W. L. Gore & Associates, INC. | $256.60 | 2022-2024 | Gore Cardioform Septal Occluder |
| Philips North America LLC | $254.98 | 2022-2025 | Igt Devices Undivided |
| Cardiovascular Systems INC. | $239.98 | 2021-2022 | |
| Pfizer INC. | $214.49 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $198.41 | 2020-2021 | |
| Amgen INC. | $184.58 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surmodics, INC. | $155.31 | 2022 | |
| Astellas Pharma US INC | $152.84 | 2021 | |
| United Therapeutics Corporation | $119.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $90.90 | 2022-2024 | |
| Shockwave Medical, INC | $77.40 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Esperion Therapeutics, INC. | $52.51 | 2020-2021 | |
| Angiodynamics, INC. | $51.12 | 2022 | |
| Lantheus Medical Imaging, INC. | $47.80 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $45.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $43.61 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $19.08 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Madonis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.